Evidence map›Paper›PMID 40788101›Full record

ArticleIndian dermatology online journal2025

Insights into the Impact of Artificial Intelligence on Psoriasis Treatment Strategies: A Mini Review.

A Prithiviraj, M A Aarthi, N Venkateswaramurthy

Abstract read
In one paragraph

Article in Indian dermatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

A PrithivirajDepartment of Pharmacy Practice, J.K.K. Nattraja College of Pharmacy, Komarapalayam, Namakkal District, Tamil Nadu, India.ORCID 0009-0000-3129-7327
N VenkateswaramurthyORCID 0000-0002-8623-7898

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractPsoriasis is a chronic inflammatory skin condition affecting millions of people globally, with prevalence varying significantly between countries. Conventional treatments, including topical agents, phototherapy, and systemic medications, often fail to account for individual variability, leading to suboptimal outcomes and potential adverse effects. Artificial intelligence (AI) has emerged as a promising approach to enhance precision and personalization in psoriasis management, potentially transforming diagnostic accuracy and treatment selection. This review examines the integration of AI across multiple domains of psoriasis treatment: (1) machine learning algorithms for phototherapy outcome prediction, (2) deep learning techniques for lesion segmentation and severity assessment, (3) AI-enhanced remote photographic monitoring systems, and (4) predictive modeling for response to systemic therapies and biologics. The analysis encompasses various AI methodologies, including random forest classifiers, convolutional neural networks, multiscale superpixel clustering, and gradient-boosted decision trees applied to clinical datasets, imaging analysis, and multi-omic patient data. AI-driven models demonstrate significant clinical utility with phototherapy outcome prediction, achieving high sensitivity (>84%) and accuracy (75-85%). Automated lesion segmentation reaches 86.99%-pixel accuracy, while remote AI assessments strongly correlate with clinical evaluations (Intraclass Correlation Coefficient [ICC] = 0.78-0.99). Notably, predictive models can forecast biologic therapy responses with > 95% accuracy within 2-4 weeks of treatment initiation, substantially reducing evaluation timelines from the conventional 12-week assessment period. AI technologies offer transformative potential in psoriasis management by enabling precise diagnosis, outcome prediction, and personalized therapy selection. Current implementations show promising results across diverse clinical applications, from phototherapy optimization to biologic response prediction. While challenges in dataset diversity, standardization, and validation remain, these represent opportunities for further advancement toward precision medicine in dermatology.

Indexed as

Identifiers

PMID40788101
PMCPMC12622942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.